AR027443A1 - MUTANTES DE EHV gM-NEGATIVOS - Google Patents
MUTANTES DE EHV gM-NEGATIVOSInfo
- Publication number
- AR027443A1 AR027443A1 ARP010100708A ARP010100708A AR027443A1 AR 027443 A1 AR027443 A1 AR 027443A1 AR P010100708 A ARP010100708 A AR P010100708A AR P010100708 A ARP010100708 A AR P010100708A AR 027443 A1 AR027443 A1 AR 027443A1
- Authority
- AR
- Argentina
- Prior art keywords
- ehv
- methods
- viruses
- refers
- nucleic acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/27—Equine rhinopneumonitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se refiere a virus herpes equinos (EHV), en donde la proteína gM está esencialmente ausente, o está modificada y no es funcional con respecto a sucapacidad inmunomoduladora. Aspectos adicionales de la invencion se refieren a ácidos nucleicos que codi fican dichos virus, a composiciones farmacéuticas quecomprenden a estos virus o a ácidos nucleicos y a sus usos. Se refiere también a métodos para mejorar la respuesta inmunitaria inducida por una vacuna de EHVfrente a infecciones de EHV de tipo salv aje, a métodos para la profilaxis y el tratamiento de infecciones de EHV y a métodos para distinguir animalesinfestados con EHV de tipo salvaje de animales tratados con EHVs de acuerdo con la invencion.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00103241A EP1129722A1 (en) | 2000-02-17 | 2000-02-17 | gM-negative EHV-mutants |
Publications (1)
Publication Number | Publication Date |
---|---|
AR027443A1 true AR027443A1 (es) | 2003-03-26 |
Family
ID=8167872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100708A Pending AR027443A1 (es) | 2000-02-17 | 2001-02-16 | MUTANTES DE EHV gM-NEGATIVOS |
Country Status (24)
Country | Link |
---|---|
US (3) | US6703231B2 (es) |
EP (2) | EP1129722A1 (es) |
JP (1) | JP5177927B2 (es) |
KR (1) | KR100845192B1 (es) |
CN (2) | CN100378216C (es) |
AR (1) | AR027443A1 (es) |
AT (1) | ATE422363T1 (es) |
AU (2) | AU4831301A (es) |
BR (1) | BR0108442A (es) |
CA (1) | CA2399846C (es) |
CO (1) | CO5280143A1 (es) |
CY (1) | CY1109023T1 (es) |
CZ (1) | CZ303657B6 (es) |
DE (1) | DE60137621D1 (es) |
DK (1) | DK1259258T3 (es) |
ES (1) | ES2322236T3 (es) |
HK (1) | HK1052462A1 (es) |
HU (1) | HU228217B1 (es) |
MX (1) | MXPA02008009A (es) |
NZ (1) | NZ521365A (es) |
PL (1) | PL210441B1 (es) |
PT (1) | PT1259258E (es) |
UY (1) | UY26588A1 (es) |
WO (1) | WO2001060403A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1129722A1 (en) | 2000-02-17 | 2001-09-05 | Boehringer Ingelheim Vetmedica Gmbh | gM-negative EHV-mutants |
US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
DE10233064A1 (de) * | 2002-07-19 | 2004-02-05 | Boehringer Ingelheim Vetmedica Gmbh | gM-negative EHV-Mutanten ohne heterologe Elemente |
AR040601A1 (es) | 2002-07-19 | 2005-04-13 | Boehringer Ingelheim Vetmed | Mutantes ehv negativos de gm sin elementos heterologos |
EP1394258A1 (en) * | 2002-08-30 | 2004-03-03 | Geneart GmbH | Non-human herpesviruses as vectors |
JP2022523564A (ja) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | 機械学習を使用するデータ圧縮および通信 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731188A (en) * | 1986-11-20 | 1998-03-24 | Syntro Corporation | Recombinant equine herpesviruses |
GB9014950D0 (en) * | 1990-07-06 | 1990-08-29 | Univ Glasgow | Ehv-4 glycoprotein vaccine |
US5674735A (en) * | 1990-07-06 | 1997-10-07 | University Court Of The University Of Glasgow | DNA encoding the EHV-4 gH or gC glycoprotein |
DE4110962A1 (de) * | 1991-04-05 | 1992-10-08 | Bayer Ag | Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen |
WO1993024528A1 (en) * | 1992-06-01 | 1993-12-09 | The University Of Melbourne | Equine herpesvirus glycoproteins |
US6193983B1 (en) * | 1992-06-01 | 2001-02-27 | The University Of Melbourne | Equine herpesvirus glycoproteins |
US5853715A (en) * | 1996-08-16 | 1998-12-29 | Bayer Corporation | Cross-protective equine herpesvirus preparations and method of making and using the same |
GB9625968D0 (en) | 1996-12-13 | 1997-01-29 | Univ Glasgow | Vaccine |
GB9626029D0 (en) * | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
AU758604B2 (en) | 1998-07-31 | 2003-03-27 | Intervet International B.V. | Attenuated equine herpesvirus |
HUP0202738A3 (en) | 1999-09-10 | 2003-12-29 | Akzo Nobel Nv | Equine herpes virus temperature sensitive mutant and live vaccine thereof |
EP1129722A1 (en) | 2000-02-17 | 2001-09-05 | Boehringer Ingelheim Vetmedica Gmbh | gM-negative EHV-mutants |
AR031599A1 (es) | 2000-07-27 | 2003-09-24 | Res Corp Technologies Inc | Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz |
DE10233064A1 (de) | 2002-07-19 | 2004-02-05 | Boehringer Ingelheim Vetmedica Gmbh | gM-negative EHV-Mutanten ohne heterologe Elemente |
AR040601A1 (es) * | 2002-07-19 | 2005-04-13 | Boehringer Ingelheim Vetmed | Mutantes ehv negativos de gm sin elementos heterologos |
-
2000
- 2000-02-17 EP EP00103241A patent/EP1129722A1/en not_active Withdrawn
-
2001
- 2001-02-15 AU AU4831301A patent/AU4831301A/xx active Pending
- 2001-02-15 DE DE60137621T patent/DE60137621D1/de not_active Expired - Lifetime
- 2001-02-15 BR BR0108442-9A patent/BR0108442A/pt active Pending
- 2001-02-15 ES ES01921280T patent/ES2322236T3/es not_active Expired - Lifetime
- 2001-02-15 WO PCT/EP2001/001672 patent/WO2001060403A1/en active IP Right Grant
- 2001-02-15 JP JP2001559499A patent/JP5177927B2/ja not_active Expired - Fee Related
- 2001-02-15 CZ CZ20022809A patent/CZ303657B6/cs not_active IP Right Cessation
- 2001-02-15 PT PT01921280T patent/PT1259258E/pt unknown
- 2001-02-15 EP EP01921280A patent/EP1259258B1/en not_active Expired - Lifetime
- 2001-02-15 KR KR1020027009566A patent/KR100845192B1/ko not_active IP Right Cessation
- 2001-02-15 CN CNB018051413A patent/CN100378216C/zh not_active Expired - Fee Related
- 2001-02-15 CA CA2399846A patent/CA2399846C/en not_active Expired - Fee Related
- 2001-02-15 DK DK01921280T patent/DK1259258T3/da active
- 2001-02-15 AU AU2001248313A patent/AU2001248313B2/en not_active Ceased
- 2001-02-15 AT AT01921280T patent/ATE422363T1/de active
- 2001-02-15 HU HU0204446A patent/HU228217B1/hu not_active IP Right Cessation
- 2001-02-15 MX MXPA02008009A patent/MXPA02008009A/es active IP Right Grant
- 2001-02-15 PL PL357019A patent/PL210441B1/pl unknown
- 2001-02-15 NZ NZ521365A patent/NZ521365A/en not_active IP Right Cessation
- 2001-02-15 CN CNA2008100092949A patent/CN101230336A/zh active Pending
- 2001-02-16 US US09/789,495 patent/US6703231B2/en not_active Expired - Lifetime
- 2001-02-16 UY UY26588A patent/UY26588A1/es not_active Application Discontinuation
- 2001-02-16 AR ARP010100708A patent/AR027443A1/es active Pending
- 2001-02-16 CO CO01012551A patent/CO5280143A1/es active IP Right Grant
-
2003
- 2003-06-30 HK HK03104650.0A patent/HK1052462A1/zh unknown
- 2003-09-26 US US10/673,017 patent/US7309598B2/en not_active Expired - Lifetime
-
2007
- 2007-12-17 US US11/934,068 patent/US8017317B2/en not_active Expired - Fee Related
-
2009
- 2009-04-24 CY CY20091100460T patent/CY1109023T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3035458T3 (en) | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule | |
ATE451119T1 (de) | Untereinheit-impfstoff gegen das respiratorische synzytialvirus | |
WO2001089559A3 (en) | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine | |
AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
NO944245L (no) | Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner | |
EA200100302A1 (ru) | Способы и композиции для протективной и терапевтической генетической иммунизации | |
BRPI0113155C1 (pt) | métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b | |
CY1109023T1 (el) | Gm-αρνητικα μεταλλαγματα ehv | |
DE60130998D1 (de) | Ribavirin-enthaltende vakzine | |
BR0316291A (pt) | Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv | |
ES2561483T3 (es) | Antígenos mutantes de GAS57 y anticuerpos de GAS57 | |
AR020084A1 (es) | Pestivirus atenuados | |
AR005750A1 (es) | Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion | |
AR036793A1 (es) | Vacunas de acido nucleico que utilizan acidos nucleicos que codifican un antigeno de tumor con un acido nucleico que codifica una citoquina como adyuvante | |
CY1109206T1 (el) | gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ | |
DE50010240D1 (de) | Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze | |
AR040601A1 (es) | Mutantes ehv negativos de gm sin elementos heterologos | |
DE69633919D1 (de) | Mehrzweckvakzine gegen umhüllte viren | |
WO2004082596A3 (en) | Yersinia species compositions | |
AR041515A1 (es) | Vacuna a dna contra el virus de papiloma humano | |
ATE318321T1 (de) | Leporipox-basierende vektorvakzine | |
ES2077017T3 (es) | Vacuna contra el virus de la bronquitis infecciosa. | |
DE60035485D1 (de) | IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407 | |
BR0110791A (pt) | Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo | |
RU2020100038A (ru) | Материалы и методы, используемые для лечения респираторных заболеваний у собак |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FG | Grant, registration |